7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, announces filing of a class action lawsuit on behalf of purchasers of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) from June 17, 2015 through August 10, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Dr. Reddy’s investors under the federal securities laws.
To join the Dr. Reddy’s class action, go to http://www.rosenlegal.com/cases-1191.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 24, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1191.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
